Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 6 of 13.
Jul 2018
18 Jul · Corporate Insolvency Resolution Process
Jun 2018
May 2018
29 May · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.28 May · Updates
28 May · Board meeting
Apr 2018
Feb 2018
Dec 2017
Nov 2017
15 Nov · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....10 Nov · Board meeting
1 Nov · Regulation 40(9) Of SEBI (LODR) Regulations, 2015
Oct 2017
21 Oct · Shareholding for the Period Ended September 30, 2017
Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click ....6 Oct · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is awaited.6 Oct · Board meeting
Sep 2017
20 Sep · Updates
15 Sep · Updates
12 Sep · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.